Identification of biomarkers which is useful for predicting the efficacy and treatment selection of immune checkpoint inhibitors
Project/Area Number |
18K15331
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
Research Institution | Fukuoka University |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2022-03-31
|
Project Status |
Completed (Fiscal Year 2021)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2021: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | 免疫チェックポイント阻害剤 / がん免疫療法 / 腫瘍免疫 / 腫瘍微小環境 / バイオマーカー / HLAクラスI APM関連分子 / 胃癌 |
Outline of Final Research Achievements |
In recent years, the therapeutic effects of immune checkpoint inhibitors (ICIs) have made a significant impact on the world, and their combination with chemotherapy has already appeared in clinical practice and is becoming a key drug for cancer pharmacotherapy. However, ICIs have some problems that need to be resolved urgently, including high drug costs, lack of sensitive biomarkers that can predict efficacy, and the risk of serious immune-related adverse events (irAEs). In six related projects to advance this research agenda, we were able to evaluate the tumor microenvironment (TME) in tumor tissue and immune cells in the peripheral blood in patients with various carcinomas. And also, we could evaluate the association between these results and therapeutic outcomes.
|
Academic Significance and Societal Importance of the Research Achievements |
次項に示す6つのプロジェクトの研究成果により、免疫チェックポイント阻害剤(ICI)による効果予測に有用なバイオマーカーの同定や、治療の有効性を高める治療戦略の選定、薬剤感受性の改善、薬剤耐性獲得への対策につながる研究を促進させるための重要な情報を提供できたと考えられ、これらの研究成果をさらに発展させることで国家の医療費の削減やICI治療を受ける患者さんのリスク軽減に直接寄与できる結果を得ることが可能になると考える。
|
Report
(5 results)
Research Products
(11 results)
-
-
[Journal Article] A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3?Specific CAR T Cells in Solid Tumors2021
Author(s)
Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S.
-
Journal Title
Clinical Cancer Research
Volume: 27
Issue: 13
Pages: 3757-3771
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
-
[Journal Article] Role of Tumor Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).2019
Author(s)
Cai L, Michelakos T, Deshpande V, Arora KS, Yamada T, Ting DT, Taylor MS, Fernandez-Del Castillo C, Warshaw AL, Lillemoe KD, Ferrone S, Ferrone CR
-
Journal Title
Clin Cancer Res.
Volume: 25
Issue: 8
Pages: 2644-2655
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
-
-